MyoBiota exists to develop naturally occurring compounds as therapeutics for muscle disease, atrophy, and weakness - with compelling preclinical evidence and a clear path to human clinical trials.
MyoBiota's platform is built on naturally occurring metabolites with demonstrated efficacy in preclinical models of muscle disease, offering a differentiated path in a space with limited therapeutic options.
Our lead candidates - pipecolic acid and succinate - are endogenous metabolites with established safety profiles, reducing de novo toxicity risk and supporting an accelerated regulatory pathway.
Targeting the underlying metabolic drivers of muscle wasting, our compounds address muscle atrophy and weakness across multiple etiologies including sarcopenia, muscle damage, and disuse-related muscle loss.
Robust preclinical evidence demonstrates significant efficacy for our lead compounds in muscle disease models, providing a compelling scientific foundation.
Our clinical development follows FDA guidance for therapeutic development. Phase 0 exploratory IND trials are designed to rapidly establish human pharmacokinetics and safety profiles.
cGMP-compliant manufacturing partnerships are under negotiation. We have identified strategic partners for clinical-grade pipecolic acid and succinate supply via GRAS-certified bacterial production.
Comprehensive patents filed covering therapeutic use of pipecolic acid and succinate for muscle disorders. Strategic production method IP is being developed to create more valuable licensing packages.
MyoBiota's research centers on two endogenous metabolites - pipecolic acid and succinate - that have demonstrated significant efficacy in treating muscle-related disorders in preclinical studies.
Because these compounds are naturally occurring, they carry inherently favorable safety profiles and offer a compelling path through regulatory review compared to novel synthetic molecules.
MyoBiota is advancing two lead compounds across multiple muscle disease indications, with FDA-guided clinical development pathways in place.
Five co-founders with expertise spanning clinical development, research science, and business operations - distributed across Kentucky, Alabama, and California.
We welcome conversations with investors, pharmaceutical partners, clinical collaborators, and institutions interested in advancing muscle disease therapeutics.